3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
5
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Head and Neck Neoplasms
7
Neoplasms
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Hypoparathyroidism
2
Carcinoma, Squamous Cell
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Diseases
1
Recurrence
1
Rectal Neoplasms
1
Parathyroid Diseases
1
Ovarian Neoplasms
1
Neovascularization, Pathologic
1
Melanoma
1
Margins of Excision
1
Lymphedema
1
Head and Neck Carcinoma
1
Graves Disease
1
Goiter
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Adenoma
1
Interventions
pembrolizumab
30
Nivolumab
10
Cyclophosphamide
9
fludarabine
7
atezolizumab
7
aldesleukin
5
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
5
Carboplatin
5
Biopsy
5
cemiplimab
4
Trastuzumab
4
Interleukin-2
4
Docetaxel
4
Cisplatin
4
spartalizumab
3
durvalumab
3
Specimen Handling
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Fulvestrant
3
Fluorouracil
3
tisotumab vedotin
2
tislelizumab
2
palbociclib
2
fludarabine phosphate
2
entinostat
2
avelumab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Indocyanine Green
×
Head & Neck
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled